专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06333195B1 Crossless retroviral vectors 有权
标题翻译：无反转录病毒载体
公开(公告)号：US06333195B1
公开(公告)日：2001-12-25
申请号：US09479776
申请日：2000-01-07
申请人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
发明人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
IPC分类号： C12N15867
CPC分类号： C12N15/86 , C12N2740/13043 , C12N2740/13052
摘要： Retroviral vector constructs are described which have a 5′ LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3′ LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.
摘要翻译：描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中载体构建体缺乏逆转录病毒gag / pol或env 编码序列。此外，描述了gag / pol和env表达盒，其中表达盒缺少共同超过8个核苷酸的连续序列。上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

2. 发明授权

US6013517A Crossless retroviral vectors 失效
标题翻译：无反转录病毒载体
公开(公告)号：US6013517A
公开(公告)日：2000-01-11
申请号：US850961
申请日：1997-05-05
申请人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
发明人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
IPC分类号： C12N15/48 , C12N15/867 , C12N5/10 , C12N15/86
CPC分类号： C12N15/86 , C12N2740/13043 , C12N2740/13052
摘要： Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.
摘要翻译：描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中该载体构建体缺乏逆转录病毒gag / pol或env 编码序列。此外，描述了gag / pol和env表达盒，其中表达盒缺少多于8个核苷酸的连续序列。上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

3. 发明授权

US5693522A Anti-cancer immunotherapeutics 失效
标题翻译：抗癌免疫治疗
公开(公告)号：US5693522A
公开(公告)日：1997-12-02
申请号：US371922
申请日：1995-01-11
申请人： Sunil Chada , Mordechai Bodner , Douglas J. Jolly , Jack R. Barber , Caty E. DeJesus
发明人： Sunil Chada , Mordechai Bodner , Douglas J. Jolly , Jack R. Barber , Caty E. DeJesus
IPC分类号： C12N15/09 , A61K39/00 , A61K48/00 , A61P35/00 , C07K14/00 , C07K14/47 , C07K14/82 , C12N5/10 , C12N15/00 , C07H21/02 , C12N5/00
CPC分类号： C07K14/00 , C07K14/47 , C07K14/4746 , C07K14/82 , A61K39/00 , A61K48/00
摘要： The present invention provides a method of destroying selected tumor cells comprising administering to a warm-blooded animal a vector construct which directs the expression of at least one immunogenic, non-tumorigenic form of an altered cellular component normally associated with the selected tumor cells. Also provided are vector constructs which direct the expression of altered cellular components. Representative altered cellular components include ras.sup.*, p53.sup.*, Rb.sup.*, alter protein encoded by the Wilms' tumor gene, ubiquitin.sup.*, mucin.sup.*, DCC, APC, MCC, neu, an altered receptor, and bcr/abl. Also provided are recombinant viruses carrying a vector construct, target cells infected with the recombinant virus, and pharmaceutical compositions comprising the recombinant virus and a pharmaceutically acceptable carrier or diluent.
摘要翻译：本发明提供了破坏所选择的肿瘤细胞的方法，包括向温血动物施用指导至少一种免疫原性，非致瘤性形式的通常与所选择的肿瘤细胞相关的改变的细胞组分的载体构建体。还提供了引导改变的细胞组分的表达的载体构建体。代表性改变的细胞成分包括由Wilms肿瘤基因编码的ras *，p53 *，Rb *，改变的蛋白质，泛素*，粘蛋白*，DCC，APC，MCC，neu，改变的受体和bcr / abl。还提供携带载体构建体的重组病毒，用重组病毒感染的靶细胞，以及包含重组病毒和药学上可接受的载体或稀释剂的药物组合物。

4. 发明申请

US20050233959A1 Use of MDA-7 to inhibit pathogenic infectious organisms 有权
标题翻译：使用MDA-7抑制致病性感染性生物体
公开(公告)号：US20050233959A1
公开(公告)日：2005-10-20
申请号：US11001702
申请日：2004-12-01
申请人： Sunil Chada
发明人： Sunil Chada
IPC分类号： A61K38/00 , A61K38/17 , A61K38/20 , A61K48/00 , C07K14/47 , C07K14/54
CPC分类号： A61K38/20 , A61K9/0019 , A61K48/00 , C07K14/4748 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479
摘要： Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.
摘要翻译：通过病原体抑制或预防受试者感染的方法涉及向受试者施用包含治疗有效量的MDA-7多肽或编码MDA-7多肽的核酸的组合物和适合的药学上可接受的制剂用于递送到受试者，其中MDA-7抑制或预防感染。还公开了抑制或预防细胞病毒感染的方法，包括获得MDA-7多肽或编码MDA-7多肽的核酸，并使细胞与MDA-7多肽或编码MDA的核酸接触 -7多肽，其中MDA-7抑制或预防细胞的感染。

5. 发明申请

US20140308247A1 Vectors Conditionally Expressing Protein 有权
标题翻译：有条件表达蛋白质的载体
公开(公告)号：US20140308247A1
公开(公告)日：2014-10-16
申请号：US14001943
申请日：2012-03-02
申请人： Jeremiah F. Roeth , Brandon Cuthbertson , Charles C. Reed , Sunil Chada , William E. Fogler , Fayas Khazi
发明人： Jeremiah F. Roeth , Brandon Cuthbertson , Charles C. Reed , Sunil Chada , William E. Fogler , Fayas Khazi
IPC分类号： A61K48/00 , C12N15/86
CPC分类号： A61K48/0025 , A61K38/1816 , A61K38/208 , A61K38/212 , A61K48/0066 , A61K48/0075 , C07K14/4713 , C07K14/505 , C07K14/5428 , C07K14/5434 , C07K14/56 , C07K14/565 , C07K14/70567 , C07K2319/70 , C07K2319/715 , C07K2319/81 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2830/002 , C12N2830/75 , C12N2830/85 , C12N2840/203
摘要： This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
摘要翻译：本发明涉及治疗领域。最具体地，本发明提供了在活化配体存在下在基因表达调节系统的控制下有条件地表达一种或多种蛋白质的方法以及用于动物治疗目的的用途。可以提供载体来治疗或预防疾病。

6. 发明申请

US20130195800A1 Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof 审中-公开
标题翻译：有条件地表达治疗性蛋白质的载体，包含载体的宿主细胞及其用途
公开(公告)号：US20130195800A1
公开(公告)日：2013-08-01
申请号：US13636473
申请日：2011-03-23
申请人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler
发明人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler
IPC分类号： C12N15/861 , A61K38/44 , A61K38/19 , A61K38/21 , A61K38/20 , A61K48/00
CPC分类号： C12N15/85 , A61K38/191 , A61K38/208 , A61K38/212 , A61K38/44 , A61K48/0066 , C07K14/5434 , C12N5/0639 , C12N15/86 , C12N15/861 , C12N2710/10343 , C12N2830/002 , C12N2840/203 , Y02A50/463
摘要： This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
摘要翻译：本发明涉及治疗领域。最具体地，本发明提供了在活化配体的存在下在基因表达调节系统的控制下产生用于一种或多种免疫调节剂的条件表达载体的方法，以及用于动物治疗目的的用途。可以提供这些载体以通过直接注射或通过体外工程化的细胞例如树突状细胞治疗多种疾病，例如肿瘤性疾病。

7. 发明申请

US20070281041A1 Compositions and Methods Involving MDA-7 for the Treatment of Cancer 审中-公开
标题翻译：涉及MDA-7治疗癌症的组合物和方法
公开(公告)号：US20070281041A1
公开(公告)日：2007-12-06
申请号：US11741594
申请日：2007-04-27
申请人： Rajagopal Ramesh , Sunil Chada
发明人： Rajagopal Ramesh , Sunil Chada
IPC分类号： A61K31/7052 , A61K31/166 , A61K31/517 , A61K33/24 , A61K45/00 , C12N15/00 , C12N5/02 , A61P35/00 , A61K38/02 , A61K31/7068 , A61K31/535
CPC分类号： A61K38/02 , A61K45/06
摘要： The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid and an EGFR inhibitor for the treatment of cancer. In certain embodiments, the invention specifically concerns a small molecule tyrosine kinase inhibitor, for example, erlotinib, as the EGFR inhibitor.
摘要翻译：本发明涉及涉及用于治疗癌症的MDA-7蛋白或编码MDA-7的核酸和EGFR抑制剂的方法和组合物。在某些实施方案中，本发明具体涉及作为EGFR抑制剂的小分子酪氨酸激酶抑制剂，例如厄洛替尼。

8. 发明申请

US20060063697A1 Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses 审中-公开
标题翻译：用野生型自身基因转导的树突状细胞引起有效的抗肿瘤免疫应答
公开(公告)号：US20060063697A1
公开(公告)日：2006-03-23
申请号：US11269112
申请日：2005-11-08
申请人： Dmitry Gabrilovich , David Carbone , Sunil Chada , Abner Mhashilkar
发明人： Dmitry Gabrilovich , David Carbone , Sunil Chada , Abner Mhashilkar
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/53 , A61K2039/54 , C12N2710/10343
摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increaed or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells. The present invention thus provides immunotherapies for treating hyperproliferative and pathogen diseases by attenuating the natural immune systems CTL response against hyperproliferative cells or overexpressing mutant p53 antigens.
摘要翻译：本发明涉及用于治疗人的过度增殖性疾病或病原体诱发的疾病的免疫治疗方法。更具体地，在一个实施方案中，本发明涉及用过度增殖性疾病治疗受试者的方法，其中自身基因的表达在过度增殖细胞中上调。在另一个实施方案中，包含在真核细胞中可操作的启动子控制下的自身基因的腺病毒表达构建体被皮内施用于所述过度增殖细胞。在本发明的另一个实施方案中，病原体诱导的病原体基因表达增加或改变的疾病是通过在真核细胞中可操作的启动子的真皮内施用病原体基因来治疗的。因此，本发明提供了通过减弱天然免疫系统CTL对抗过度增殖细胞或过表达突变型p53抗原来治疗过度增殖和病原体疾病的免疫疗法。

9. 发明授权

US08668905B2 P53 vaccines for the treatment of cancers 有权
标题翻译： P53疫苗用于治疗癌症
公开(公告)号：US08668905B2
公开(公告)日：2014-03-11
申请号：US11433079
申请日：2006-05-12
申请人： Scott Antonia , Dmitry I. Gabrilovich , Sunil Chada , Kerstin B. Menander
发明人： Scott Antonia , Dmitry I. Gabrilovich , Sunil Chada , Kerstin B. Menander
IPC分类号： A01N63/00 , A01N65/00
CPC分类号： A61K39/0011 , A61K45/06 , A61K47/6901 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/572 , A61K2039/585
摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
摘要翻译：本发明涉及用于治疗人的过度增殖性疾病的免疫治疗方法，特别是治疗难治的过度增殖性疾病。更具体地，在一个实施方案中，本发明涉及治疗具有过度增殖性疾病的受试者的方法，其中自身基因的表达在耐药性过度增殖细胞中上调。在另一个实施方案中，将包含在真核细胞中可操作的启动子控制的自身基因的腺病毒表达构建体施用于耐药性过度增殖细胞。因此，本发明提供了通过减弱例如天然免疫系统对过度增殖细胞或过表达突变型p53抗原的CTL应答来治疗耐药性过度增殖性疾病的免疫疗法。

10. 发明申请

US20070066552A1 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids 审中-公开
标题翻译：局部给药允许目标细胞长时间暴露于治疗和预防性核酸
公开(公告)号：US20070066552A1
公开(公告)日：2007-03-22
申请号：US11336664
申请日：2006-01-20
申请人： Peter Clarke , Sunil Chada , Kerstin Menander , Robert Sobol , Shuyuan Zhang
发明人： Peter Clarke , Sunil Chada , Kerstin Menander , Robert Sobol , Shuyuan Zhang
IPC分类号： A61K48/00 , A61K9/68
CPC分类号： C07K14/4746 , A61K8/606 , A61K9/0014 , A61K9/1272 , A61K48/005 , A61K48/0075 , A61Q11/00 , A61Q19/00 , C12N15/86 , C12N2710/10343 , C12N2799/022 , C12N2830/008
摘要： Compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi-solid formation or in a transdermal or transcutaneous delivery device are disclosed. Also disclosed are compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include an adhesive. Compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid uptake enhancer are also disclosed. Methods of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that involve these therapeutic compositions and devices are also disclosed.
摘要翻译：公开了用于预防或抑制受试者中包含固体或半固体形成物或透皮或经皮递送装置中的核酸的过度增殖性病变生长的组合物和方法。还公开了能够预防或抑制包含粘合剂的受试者中过度增殖性损伤的生长的核酸的组合物。还公开了能够预防或抑制受试者中包含核酸摄取增强剂的过度增殖性损伤的生长的核酸的组合物。还公开了预防或抑制涉及这些治疗组合物和装置的受试者中过度增殖性病变生长的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式